Haldol

Haldol is the brand name for the oral antipsychotic medication haloperidol, a butyrophenone derivative supplied in the European market. The product contains the active ingredient haloperidol, though specific strength and dosage form details are not disclosed. It is a prescription‑only drug that works primarily as a dopamine D2 receptor antagonist and is used under medical supervision for various psychiatric conditions and may be prescribed by psychiatrists or other qualified clinicians.

Haloperidol (Haldol) is indicated for several psychiatric and neurological conditions where dopamine dysregulation contributes to symptoms.

- Schizophrenia, including maintenance therapy for chronic disease - Acute psychotic episodes or severe agitation requiring rapid control - Manic episodes associated with bipolar disorder when other agents are insufficient - Tourette syndrome, particularly for patients with disabling motor or vocal tics - Adjunctive treatment of severe behavioral disturbances in dementia (off‑label in some regions)

Haloperidol may produce a range of adverse effects that vary in frequency and severity.

Common: - Drowsiness or sedation, especially when therapy is initiated - Extrapyramidal symptoms such as tremor, rigidity, akathisia, or dystonia - Dry mouth, increased salivation, or changes in taste perception - Constipation, nausea, or other gastrointestinal discomfort - Blurred vision, dizziness, or orthostatic light‑headedness

Serious: - Tardive dyskinesia, a potentially irreversible involuntary movement disorder - Neuroleptic malignant syndrome, with fever, rigidity, autonomic instability, and altered mental status - Severe hypotension or cardiac arrhythmias, including QT prolongation - Elevated prolactin levels causing galactorrhea, gynecomastia, or menstrual irregularities - Agranulocytosis or severe leukopenia, leading to increased infection risk

When prescribing haloperidol, clinicians should evaluate patient history and monitor for conditions that may increase risk of adverse outcomes.

- History of cardiovascular disease, arrhythmias, or prolonged QT interval - Pre‑existing movement disorders or Parkinsonian features - Severe hepatic or renal impairment affecting drug clearance - Pregnancy, breastfeeding, or women of childbearing potential (risk not well defined) - Elderly patients, especially those with dementia, due to higher sensitivity to sedation and extrapyramidal effects - Concomitant use of other central nervous system depressants

Haloperidol can interact with several medications, altering its efficacy or increasing the likelihood of serious side effects.

Avoid: - Other potent dopamine antagonists or high‑dose antipsychotics - Drugs that significantly prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics) - Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin

Use with caution: - CYP3A4 inducers like carbamazepine or rifampin, which may reduce haloperidol levels - CNS depressants including benzodiazepines, opioids, or alcohol - Anticholinergic agents that may mask extrapyramidal symptoms